Skip to main content
Clinical Trials/NCT07296614
NCT07296614
Not yet recruiting
Phase 3

Integrative Chinese and Western Medicine for Diminished Ovarian Reserve-Associated Infertility in Natural Conception Population

Peking Union Medical College Hospital1 site in 1 country320 target enrollmentStarted: December 25, 2025Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Enrollment
320
Locations
1
Primary Endpoint
Cumulative clinical pregnancy rate

Overview

Brief Summary

This study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen ("Xiehe DOR Bushen Tongzhi Formula" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulation induction therapy with ovulation monitoring and timed intercourse) in improving the natural cumulative clinical pregnancy rate in infertile patients with kidney deficiency-type diminished ovarian reserve (DOR).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
22 Years to 39 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Female patients aged 22 to 39 years (inclusive).
  • Meet the diagnostic criteria for diminished ovarian reserve (requiring at least two of the following: Basal FSH 10-25 IU/L; AMH \< 1.1 ng/mL; AFC \< 7) and infertility(defined as the failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse).
  • Meet the diagnostic criteria for kidney deficiency syndrome in traditional Chinese medicine
  • Voluntarily participate in this study and provide written informed consent.

Exclusion Criteria

  • Patients with premature ovarian insufficiency or premature ovarian failure (basal FSH \>25 IU/L), organic pathologies such as ovarian tumors, endometrial tuberculosis, intrauterine adhesions, or endometrial injuries, as well as those with congenital adrenal hyperplasia or Cushing's syndrome;
  • Infertility caused by organic lesions of the fallopian tubes, uterus, cervix, etc.
  • Infertility due to male factors (based on semen analysis reports, meeting the diagnostic criteria for oligoasthenoteratozoospermia according to the WHO 5th edition standards).
  • DOR caused by iatrogenic factors (such as pelvic surgery, radiotherapy/chemotherapy, uterine artery embolization, etc.).
  • Patients with severe primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, or psychiatric disorders.
  • Individuals with known allergies to the investigational drug or its components.
  • Use of hormonal medications (e.g., estrogen, contraceptive drugs) within one month prior to enrollment, or use of kidney-tonifying Chinese herbal medicines or proprietary Chinese medicinal products within one month prior to enrollment.
  • Patients currently participating in or planning to participate in other clinical trials.

Arms & Interventions

Western medicine group

Placebo Comparator

Take the placebo granules orally for three months, followed by three cycles of letrozole while continuing the placebo.

Intervention: Western Medicine (Drug)

Western medicine group

Placebo Comparator

Take the placebo granules orally for three months, followed by three cycles of letrozole while continuing the placebo.

Intervention: Placebo (Drug)

Integrated traditional Chinese and Western medicine

Experimental

Take the "Xiehe DOR Kidney-Tonifying Universal Formula" orally for three months; thereafter, continue the Chinese herbal formula while combining it with three cycles of letrozole.

Intervention: Western Medicine (Drug)

Integrated traditional Chinese and Western medicine

Experimental

Take the "Xiehe DOR Kidney-Tonifying Universal Formula" orally for three months; thereafter, continue the Chinese herbal formula while combining it with three cycles of letrozole.

Intervention: Traditional Chinese Medicine (Drug)

Outcomes

Primary Outcomes

Cumulative clinical pregnancy rate

Time Frame: Assessed at study completion, approximately 6 months after enrollment.

The rate of intrauterine pregnancy confirmed by transvaginal ultrasound

Secondary Outcomes

  • Indicators related to ovarian reserve function(Baseline, 3-months, 6-months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials